RSV Season Ends April 15
Based on decreased RSV test positivity and pediatric hospitalizations, the Philadelphia Department of Public Health recommends stopping RSV monoclonal antibody immunization (i.e., nirsevimab and clesrovimab) to all eligible patients on April 15, 2026. Administration may continue until April 30, 2026, based on clinical judgment. Due to...